Maximizing TBI Rehabilitation Outcomes with Targeted Interventions

doi:10.1016/j.apmr.2009.01.004

Archives of Physical Medicine and Rehabilitation

Volume 90, Issue 3, March 2009, Page 530

https://doi.org/10.1016/j.apmr.2009.01.004 Get rights and content

References (7)

R.D. Vanderploeg et al.
Rehabilitation of traumatic brain injury in active duty military personnel and veterans: defense and veterans brain injury center randomized controlled trial of two rehabilitation approaches
Arch Phys Med Rehabil
(2008)
G.M. Giles et al.
Brain injury rehabilitation: a neurofunctional approach
(1993)
M. Sohlberg et al.
APT: Attention process training manual
(1987)

There are more references available in the full text version of this article.

Cited by (5)

Synergistic benefits of erythropoietin and simvastatin after traumatic brain injury
2010, Brain Research
Citation Excerpt :
Current pharmacological and surgical treatments for TBI remain limited which include surgical removal of hematoma, ventricular drainage, hyperosmotic agents, and hypothermia that are known to prevent neurological deterioration to a certain extent, but not sufficient enough for full recovery after TBI (Christian et al., 2008; Nichol and Cooper, 2009 ; Wang et al., 2007; Wheaton et al., 2009 ). Given the heterogeneous nature of TBI involving complex primary and secondary events, TBI candidate therapies targeted towards multiple injury factors are likely to maximize successful outcome (Giles, 2009; Saatman et al., 2008). Current therapeutic limitations of TBI may be attributed to the fact that most of the therapies are “monotherapies” involving the use of a single agent targeted toward an individual injury factor (Margulies and Hicks, 2009; Vink and Nimmo, 2009).
Simvastatin and recombinant human erythropoietin (rhEpo) are implicated as potential therapeutic candidates for traumatic brain injury (TBI). Prominent effects of simvastatin include its anti-inflammatory, neurotrophic and neuroregenerative actions studied in various models of neuronal injury. On the other hand, rhEpo has been shown to promote cell survival mechanisms by producing anti-apoptotic and cell proliferative actions. Beneficial effects of rhEpo and statin monotherapies have been well studied. However, there are no reports showing combined use of rhEpo and statins after TBI. This investigation examined if combined efficacy of cell proliferative ability of rhEpo along with the neuroregenerative ability of simvastatin will render maximum recovery in a controlled cortical impact (CCI) mouse model of TBI. Results showed that compared to baseline TBI, rhEpo was more effective than simvastatin in promoting cell proliferation while simvastatin was more effective than rhEpo in restoring axonal damage following TBI. Combined treatment with simvastatin and rhEpo maximally restored axonal integrity while simultaneously inducing greater proliferation of newly formed cells resulting in better functional recovery after TBI than either alone. This is the first study showing the efficacy of erythropoietin–simvastatin combinational therapeutic approach in achieving greater structural and cognitive recovery after TBI.
Revisiting the neurofunctional approach: Conceptualizing the core components for the rehabilitation of everyday living skills
2014, Brain Injury
Neural regenerative engineering
2013, Regenerative Engineering
Toward a convergence of regenerative medicine, rehabilitation, and neuroprosthetics
2011, Journal of Neurotrauma
Cognitive versus functional approaches to rehabilitation after traumatic brain injury: Commentary on a randomized controlled trial
2010, American Journal of Occupational Therapy

View full text

DepartmentLetter to the EditorMaximizing TBI Rehabilitation Outcomes with Targeted Interventions

Arch Phys Med Rehabil

Brain injury rehabilitation: a neurofunctional approach

APT: Attention process training manual

Department
Letter to the Editor
Maximizing TBI Rehabilitation Outcomes with Targeted Interventions